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ABSTRACT
Human breast tumors harbor supernumerary centrosomes in almost 80% of
tumor cells. Although amplified centrosomes compromise cell viability via multipolar
spindles resulting in death-inducing aneuploidy, cancer cells tend to cluster extra
centrosomes during mitosis. As a result cancer cells display bipolar spindle phenotypes
to maintain a tolerable level of aneuploidy, an edge to their survival. HSET/KifC1,
a kinesin-like minus-end directed microtubule motor has recently found fame as a
crucial centrosome clustering molecule. Here we show that HSET promotes tumor
progression via mechanisms independent of centrosome clustering. We found that
HSET is overexpressed in breast carcinomas wherein nuclear HSET accumulation
correlated with histological grade and predicted poor progression-free and overall
survival. In addition, deregulated HSET protein expression was associated with gene
amplification and/or translocation. Our data provide compelling evidence that HSET
overexpression is pro-proliferative, promotes clonogenic-survival and enhances cellcycle kinetics through G2 and M-phases. Importantly, HSET co-immunoprecipitates
with survivin, and its overexpression protects survivin from proteasome-mediated
degradation, resulting in its increased steady-state levels. We provide the first
evidence of centrosome clustering-independent activities of HSET that fuel tumor
progression and firmly establish that HSET can serve both as a potential prognostic
biomarker and as a valuable cancer-selective therapeutic target.

INTRODUCTION

altered centrosome function in microtubule nucleation and
organization [2]. Centrosome amplification can initiate
tumorigenesis in Drosophila neuroblasts [3]; thus, it is
becoming recognized that centrosome amplification is
one of the primary causes of breast cancer and is not just a
consequence of malignant transformation.
The presence of more than two centrosomes
within a cell can pose a grave conundrum as it may lead
to the assembly of a multipolar mitotic spindle, and the

About 80% of invasive breast cancers exhibit
supernumerary centrosomes, a feature commonly referred
to as centrosome amplification [1]. Most breast cancers
harbor abnormalities in centrosome structure, function,
or localization within the cell. These abnormalities can
potentially cause cytoarchitectural distortion in cancer
tissues with loss of cellular differentiation (anaplasia) via
www.impactjournals.com/oncotarget
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production of nonviable progeny cells due to lethal levels
of chromosomal loss or gain (i.e., death-inducing, highgrade aneuploidy) [4]. However, cancer cells harboring
extra centrosomes circumvent these catastrophic
consequences and survive. The secret to their survival and
success, as it turns out, lies in a clever tactic that cancer
cells use to sidestep spindle multipolarity, viz., centrosome
clustering, whereby the excess centrosomes are artfully
corralled into two polar foci to enable formation of a
pseudo-bipolar mitotic spindle [5, 6]. During a preceding,
transient, multipolar state, merotelic kinetochoremicrotubule attachments occur, thus engendering lowgrade whole chromosome missegregation that could be
‘tumor-promoting’ [7].
HSET/KifC1, a minus end-directed motor protein
that promotes microtubule cross-linking, sliding,
bundling and spindle pole focusing, has been recently
identified as an essential mediator of supernumerary
centrosome clustering in cancer cells [8]. HSET has also
been shown to be indispensable for the clustering of
acentrosomal microtubule organizing centers (MTOCs)
whose production tends to be hyperactivated in cancer
cells. HSET knockdown in cells with supernumerary
centrosomes causes excess centrosomes to be scattered
by pole-separating forces, leading to rampant spindle
multipolarity and cell death [9]. By contrast, HSET
function appears to be non-essential in healthy somatic
cells due to the presence of two centrosomes that shoulder
the responsibility of bipolar spindle assembly. In cells
devoid of centrosomes, such as oocytes, HSET function
is indispensable for the assembly of a fusiform bipolar
spindle [10].
Recently, attention has converged on HSET as a
potential chemotherapeutic target due to its intriguing
association with malignancy. RT-PCR studies have shown
that HSET’s expression level in lung cancer is associated
with increased risk of metastatic dissemination to the
brain [11]. Docetaxel resistance in breast cancer is also
suggested to be partly mediated by HSET [12]. In silico
studies reveal that HSET expression is also higher in triple
negative breast cancers compared to non-triple negative
ones [13]. The differential dependence of cancer cells on
HSET for viability and association of HSET expression
with metastases-raise the tantalizing possibility that HSET
may play a more important role in tumor progression than
previously appreciated. However, more direct evidence
of HSET’s role in clinical progression of breast cancer
and mechanistic studies revealing the molecular circuitry
involved therein are lacking.
In this study, we evaluated HSET expression in
breast carcinomas and examined its association with
clinical tumor progression. Intriguingly, we found that
HSET overexpression at the time of diagnosis was
significantly associated with worse prognosis and overall
survival. Exploration of its mechanistic role in tumor
progression unmasked plausible centrosome clusteringwww.impactjournals.com/oncotarget

-independent roles of HSET underlying enhanced tumor
cell proliferation and survival, and disease progression.
Our results substantiate the idea that HSET could be an
invaluable, cancer-cell selective therapeutic target and
may serve as a prognostic biomarker for breast cancer.

RESULTS
HSET is overexpressed in variety of human
cancers
Given the crucial requirement of centrosome
clustering mechanisms for the viability of cancer cells
with extra centrosomes, we first wanted to examine the
abundance of the clustering protein HSET in various
cancers that harbor extra centrosomes. We performed
an in silico gene expression analysis using publicallyavailable microarray data to determine the expression
level of HSET in various cancer tissue types. One-channel
microarray data for glioblastoma, leukemia, lung and
breast cancer patients with their normal sample pairs
were collected from Gene Expression Omnibus (GEO)
database [14]. Each of these samples were then Robust
Multiarray (RMA) normalized [15], and their logarithm
to base 2-transformed HSET gene expression values
were plotted to determine the difference as shown in
Fig. 1Ai-vi. Next, we determined differences in HSET
gene expression for cancer and normal sample groups
using two-tailed test of hypothesis. Our statistical results
indicated higher HSET gene expression in glioblastoma,
lung, breast, colon and cervical tumor samples as
compared to their corresponding normal tissues. All these
tumor types have been shown in various studies with
exhibit significant degrees of centrosome amplification
[16-25]. The average HSET expression for glioblastoma
(N=20) and colon cancer (N=53) patients was found
to be ~3-fold higher than normal samples (N=3 and
10, respectively) (p<0.005), followed by breast cancer
patients (N=179) with more than 5-fold higher expression
in tumors than in normal samples (N=16) (p<0.001). Our
in silico results were consistent with observations from
a previous study wherein HSET mRNA expression was
significantly elevated in a broad panel of primary tumor
tissue compared to corresponding normal tissue [9]. Our
in silico data corroborate immunohistochemical analysis
suggesting a significantly higher HSET expression in
glioblastoma, colon and cervical tumors (Fig. 1Bii, Cii,
Dii) as compared with their respective adjacent normal
tissue samples (Fig. 1Bi, Ci, Di). These data suggest HSET
overexpression as a general feature of cancers exhibiting
significant centrosome amplification.
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HSET is overexpressed in human breast cancers

tumor samples and their paired adjacent normal tissues for
HSET. An enhanced expression of HSET was observed
in 10 tumor samples compared to their normal adjacent
tissues and 7 representative normal/tumor sample pairs are
shown in Fig. 2A. The remaining 6 normal/tumor pairs
showed negligible overexpression of HSET (data not
shown). Additionally, HSET expression in most human
breast cancer cell lines was much higher than in noncancerous or pre-malignant cell lines such as NIH3T3 and
MCF10 series (MCF10A, MCF10AT1, MCF10DCIS)
(Fig. 2B), indicating that HSET overexpression typifies
breast cancer cells.

Our in silico analyses of microarray data showed
that breast cancers display significantly higher HSET
expression (~5-fold) than corresponding normal tissue. In
addition, given the pronounced occurrence of amplified
centrosomes and centrosome clustering in aggressive
breast cancer, we decided to focus our study on breast
cancers. To explore the role of HSET in tumor progression,
we examined whether HSET was overexpressed in human
breast tumors. We immunoblotted 16 fresh-frozen human

Figure 1: HSET overexpression in human carcinomas. (A) Scatter plots depicting HSET gene expression in normal (green dots)

versus tumor (red dots) tissues in (i) Glioblastoma, (ii) Lung carcinoma, (iii) Leukemia, (iv) breast carcinoma, (v) colon carcinoma and
(vi) cervical carcinoma. Data was obtained from one channel microarray available at GEO database. Robust multiarray normalization was
performed to obtain the differences depicted in the plots. (B, C and D) Immunohistographs showing HSET expression in glioblastoma
tissue where a representative normal tissue (N) (Bi) is compared to tumor tissue (T) (Bii), in colon tumor (Cii) versus adjacent normal (Ci)
tissue, and in cervical tumor (Dii) versus adjacent normal (Di) tissue.
www.impactjournals.com/oncotarget
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Since higher HSET protein levels could arise either
from an upregulation of transcription from the endogenous
locus and/or an amplification of the locus encoding HSET,
we decided to examine the copy numbers of the locus
encoding the HSET gene in normal and breast tumor
tissues. We performed fluorescence in situ hybridization
(FISH) to directly evaluate HSET copy number per cell
in paraffin-embedded breast tumor tissues. We hybridized
two bacterial artificial chromosome (BAC) probes to
primary breast tumor tissues, one from the HSET locus
on chromosome 6 (RPCI-11 602P21, green) and one
from the chromosome 6 centromere (CH514-7B4, red).
Amplification of HSET was visualized as an increase in
the number of HSET signals relative to the number of
control centromere signals. We scored HSET amplification
by FISH in four breast tumor tissues and found that,
among them, three tumors exhibited HSET amplifications.
No amplification of the HSET locus was observed in the
normal adjacent tissues in these samples. We observed
various types of copy number changes associated with
HSET as shown in Fig. 2C, D. FISH with the centromere
probe indicated that most increases in HSET loci were not
due to polyploidy of chromosome 6; rather, only 5% of
cells were aneuploid. 38% of cells (500 cells each were
counted from 2 tissue samples) showed 3 or more copies
of HSET paired with only 1 or 2 copies of the centromere

(Fig. 2D). More so, cancer cells isolated from fresh human
breast tumor also showed HSET amplification (Suppl. Fig.
1). These findings indicate alterations in the HSET gene
copy number during tumorigenesis. It is worth mentioning
that HSET gene amplifications in specific breast tumor
samples were correlated with increased expression of
HSET protein in all those samples using immunoblotting
methods (data not shown).

HSET overexpression correlates with breast
cancer progression and aggressiveness
Next we asked how HSET overexpression correlates
with breast cancer progression and aggressiveness.
Using an immunohistochemical approach, we stained
a total of 60 clinical specimens with 10 cases each of
normal breast, ductal hyperplasia (DH), atypical ductal
hyperplasia (ADH), ductal carcinoma in situ (DCIS),
invasive breast carcinoma (low-grade) and invasive
breast carcinoma (high-grade). In consonance with our
immunoblotting data, our immunohistochemical analysis
showed that HSET is selectively overexpressed in human
breast cancers with negligible or absence of expression
in normal breast epithelia (Fig. 3A). Intriguingly, we
observed a selective increase in nuclear staining of HSET

Figure 2: The HSET gene is overexpressed in breast cancers. (A) Cell lysates from 16 paired clinical breast tumor tissues (T) and

normal adjacent tissues (N) were analyzed for HSET protein expression by western blotting. Representative results of 7 paired samples are
shown. (B) Immunoblot showing HSET expression in a) MCF10A series of cell lines representing a continuum from near-normal breast
(MCF-10A) to pre-malignant (MCF10-AT1) to comedo ductal carcinoma in situ (MCF10-DCIS), aggressive breast cancer cell lines such
as MDA-MD-231 and T47D and normal mouse fibroblast cell line, 3T3. (C) Representative confocal micrographs showing fluorescence
in situ hybridization of two bacterial artificial chromosome (BAC) probes, one from the HSET locus on chromosome 6 (RPCI-11 602P21,
green) and one from the chromosome 6 centromere (CH514-7B4, red), to paraffin-embedded primary breast tumor tissues. Amplifications
of HSET were visualized as an increase in the number of green signals (denoted as G) relative to the number of red control centromere
signals (denoted as R), where 1R1G and 2R2G represent normal HSET gene copy numbers and 1R4G, 2R4G, 2R5G, 1R5G,etc. represent
instances wherein HSET gene locus is amplified. (D) Bar graph representation of various combinations of red and green copy numbers
observed for HSET locus and chromosome 6 centromere as determined by visual quantitation from confocal images (p<0.05). 1R1G and
2R2G are considered normal copy numbers; elevated copy numbers but same ratio of R and G signals are considered as aneuploid (3R3G,
4R4G) and all other combinations with higher G-to-R ratios are considered to represent instances where the HSET gene is amplified.
www.impactjournals.com/oncotarget
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in tumor samples. Among subtypes based on varying
types and extent of intraductal proliferation, we found a
progressive increase in HSET nuclear staining intensity
and frequency from ductal hyperplasia (DH) (Fig. 3Aii)
to atypical ductal hyperplasia (ADH) (Fig. 3Aiii) to
ductal carcinoma in situ (DCIS) (Fig. 3Aiv). In invasive
breast cancers (both low- and high- grade), HSET nuclear
staining was remarkably intense, with a significant
increase in the number of positively stained nuclei per
field in high-grade cancers (Fig. 3Av,vi) compared to lowgrade ones (Fig. 3Aii,iii,iv). A majority of normal breast
tissue samples (85%) showed no staining for HSET, while

the remainder showed very weak staining (Fig. 3Ai, data
not shown). We then calculated a weighted index score
(WI) for HSET expression as a product of the staining
intensity score (+1, +2, +3) and percentage positive nuclei
for each sample. HSET WI serves as an independent
measure of the strength of HSET protein expression across
all breast tumor specimens. Nuclear HSET WI values were
then correlated with normal and tumor samples and also
with the grade of tumor samples. Interestingly, nuclear
HSET WI showed a strong correlation with increasing
tumor grade in breast cancer (Fig. 3Bi,ii). Collectively,
these observations indicate robust HSET overexpression

Figure 3: HSET overexpression correlates to increased aggressiveness and poorer clinical outcomes. Immunohistographs
showing HSET expression in (Ai) normal breast, (Aii) ductal hyperplasia, (Aiii) atypical ductal hyperplasia, (Aiv) ductal carcinoma insitu, (Av) invasive ductal carcinoma, low-grade, (Avi) invasive ductal carcinoma, high-grade. Brown (DAB) color shows HSET staining.
Intensities of nuclear HSET staining were quantified using image analysis Aperio Image Scope v.6.25 software. A weighted index score
(WI) for HSET expression was calculated and was assessed in 339 breast cancer and 19 normal samples. Box-whisker plots showing (Bi)
HSET WI score in normal breast and tumor samples, (Bii) HSET WI score across Grade I (n=40), Grade II (n=237) and Grade III (n=62)
breast cancer samples. (Ci) Probability of progression free survival of 163 breast cancer patients with HSET nuclear expression above
or below the median HSET weighted index (WI) value referred to as positive and negative, respectively (p=0.0034). (Cii) Probability of
overall survival of 163 patients with positive and negative HSET weighted index (p=0.0412). Statistical analysis was conducted using SAS
Version 9.3. Scale bar=10 µm.
www.impactjournals.com/oncotarget

6080

Oncotarget

in human breast tumors suggesting that abnormal HSET
levels correlate with breast cancer development and
HSET might play a role in progression of tumors into
more malignant and aggressive forms. Having established
a significant correlation between HSET expression and
tumor differentiation, we next asked if there was an
association of nuclear HSET WI with progression-free
survival (PFS) and overall survival (OS) in breast cancer
patients, using the biospecimens obtained from Emory
Hospital with retrospective clinical information (n=163).
While PFS was calculated as the number of days from
diagnosis to the first local recurrence or metastasis if
one occurred, or the last follow-up if the patient did not
progress, OS was based on the number of days from
diagnosis to death or last follow-up if death was not
recorded. Nuclear HSET WI was also categorized into
high and low groups based on the median. Irrespective
of the receptor status (n=163), those with higher nuclear
HSET WI (shown as HSET WI positive in Fig. 3Ci,ii) had

significantly shorter PFS (p= 0.0034) and OS (p=0.0412)
than patients with lower nuclear HSET WI (shown as
HSET WI negative in Fig. 3Ci,ii), clearly demonstrating
that higher nuclear HSET expression levels significantly
correlate with poorer clinical outcomes. Multivariate
analysis accounting for HSET nuclear expression, age,
grade and receptor status (ER, PR, HER2) revealed that
HSET nuclear expression and receptor status (negative)
significantly correlated with both OS (p=0.030 for nuclear
HSET WI, p=0.036 for PR negativity) and PFS (p=0.044
for nuclear HSET WI, p=0.003 for HER2 negativity).
Mean HSET was significantly higher (7.82 vs 5.50, p
<.0001) for triple-negative patients as opposed to nontriple-negative patients. In a wound-healing assay, we
show that HeLa cells transiently overexpressing HSET
show enhanced migration as compared to wild-type HeLa
cells (Suppl. Fig. 2). These observations strongly suggest
correlation of HSET nuclear expression with breast tumor
aggressiveness.

Figure 4: Cell proliferation is enhanced in HeLa cells that stably overexpress HSET. (A) Immunoblots showing higher

Ki67 and p-histone H3 in HeLa-HSET-GFP (denoted as HeLa HSET) cells as compared with HeLa cells. Kinase activity assay showed
higher cdk1 activity in HeLa-HSET-GFP cells as represented by the immunoblot showing enhanced phosphorylation of Histone H3 by
cdk1 as compared to HeLa cells. The two bands representing HSET expression correspond to the endogenous HSET levels (lower band)
and the GFP-HSET levels (upper band). (B) Representative confocal immunomicrographs showing higher Ki67expression (red) in HeLaHSET-GFP cells as compared with HeLa cells. (C) Randomly dividing HeLa-HSET-GFP and HeLa cells were incorporated with BrdU
and immunostained with anti-BrdU antibody (green) to visualize the cells traversing S-phase. Representative immunofluorescence images
showing higher BrdU incorporation in HeLa-HSET-GFP cells. (D) Bar graphs depicting the percent cells that are Ki67or BrdU positive in
HeLa and HeLa-HSET cells. (E) Bar graphs representing number of cells in cell proliferation assay counted by trypan blue at Day 0 and
Day 2 of seeding.
www.impactjournals.com/oncotarget
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HSET overexpression is associated with enhanced
cell proliferation

advantages to cancer cells.

HSET overexpression leads to accelerated cell
cycle kinetics

Since elevated HSET expression exhibits a strong
correlation with clinical development and progression of
cancer, we next asked if high HSET levels had any impact
on the kinetics of cancer cell proliferation in vitro. To this
end, we used HeLa cells stably transfected with HSETGFP to examine and compare the levels of various cell
proliferation markers in HeLa-HSET-GFP and HeLa cells.
Using immunoblotting methods, we found that levels of
Ki67 (found in G1, S, G2 and M-phases of the cell cycle
but is absent in G0 cells) was substantially elevated in
HeLa-HSET-GFP cells compared to wild-type HeLa cells
(Fig. 4A). This finding was consistent with the strikingly
higher Ki67 labeling index observed in HeLa-HSET-GFP
cells via immunostaining (Fig. 4B). This observation is
noteworthy since the Ki67 labeling index often correlates
with the clinical course of cancer, owing to which the
proportion of Ki67-positive cells in a cell population has
strong prognostic value for survival and tumor recurrence
in cancer patients [26, 27]. Immunofluorescent staining
for BrdU, a marker for cells undergoing S-phase, also
showed that a greater proportion of HeLa-HSET-GFP
cells were BrdU-positive compared to HeLa cells (Fig.
4C). A visual quantitation of these observations revealed
significantly elevated levels of Ki67 expression and BrdU
incorporation in HeLa-HSET-GFP cells as compared
with HeLa cells (Fig. 4D). We also observed enhanced
cdk1 activity and higher expression of phosphorylated
histone-H3 in HeLa-HSET-GFP cells compared to HeLa
cells, which is indicative of a larger proportion of cells
in the HeLa-HSET-GFP line undergoing M-phase (Fig.
4A). All these lines of evidence strongly advocate for
a pro-proliferative role for HSET overexpression in the
cellular context of cancer cells. HeLa-HSET-GFP cells
also displayed significantly enhanced cell proliferation
capacities when compared to HeLa cells in trypan blue
assay. Equal numbers of each cell type were seeded on
day 0 and were allowed to grow for 2 days (48h), and
the number of cells were counted using trypan blue.
Based on the data, the doubling time of HeLa-HSETGFP cells was found to be ~11h as compared to ~16h
for HeLa cells (Fig. 4E). We also performed colony
formation assay with HeLa cells transiently transfected
with control vector, HSET-GFP plasmid and HSET-GFP
siRNA. HSET OE cells were able to form significantly
higher number of colonies as compared to cells transfected
with control vector. Fewer colonies were observed
upon HSET knockdown (KD) (Suppl. Fig. 3). Similar
proliferation effects were confirmed by colony formation
assay in another breast cancer cell line, MDA-MB-231
upon transient HSET OE and KD (Suppl. Fig. 3). Taken
together, these data demonstrate that cells overexpressing
HSET display enhanced cell proliferation, and suggest that
HSET overexpression may confer significant proliferative
www.impactjournals.com/oncotarget

Since HSET OE enhances cellular proliferation
in HeLa cells, we were curious to examine any changes
in the cell cycle kinetics of cells that stably overexpress
HSET (HeLa-HSET-GFP cells) compared to the parental
ones. To this end, we synchronized HeLa and HeLaHSET-GFP cells using a single thymidine block (19h)
followed by 2-color flow cytometric analysis of cell cycle
profiles of HeLa-HSET-GFP and HeLa cells upon their
release from the block at G1/S border. DNA content was
analyzed with propidium iodide (PI) staining, where G2/M
population was represented by double the intensity of PI
(4N) compared to G1 cell population (2N). Anti-MPM-2
antibody tagged with Alexa488 secondary antibody was
used to detect a mitosis-specific marker (MPM-2), in
order to distinguish between 4N DNA-bearing G2 and M
populations. A close interval cell cycle profiling revealed
that HeLa-HSET-GFP cells demonstrated faster cell cycle
progression kinetics; in other words, the duration of one
complete cell cycle was reduced in HeLa-HSET-GFP cells
(10.5h) as compared with wild-type cells (13h), with a
stark shortening of the G2-and M-phases (Fig. 5A, B, C).
This experiment was performed 3 times and the average
time was represented as final duration of cell cycle phases
in Fig. 5A. This trend was reflected when cyclin B1 levels
(indicating mitotic phase) were followed in synchronized
HeLa and HeLa-HSET-GFP cells using western blotting.
While cyclin B1 levels surged at 10h followed by a decline
in HeLa cells, they peaked at 8h and then declined in
HeLa-HSET-GFP cells (Fig. 5D). Transient knockdown
(KD) of HSET in HeLa cells resulted in a marginal
increase in cell cycle duration (14h as compared to 13h
in HeLa cells) with a protracted G2/M-phase (Suppl. Fig.
4A). This observation is in accordance with previously
observed effects of HSET depletion in human fibroblast
cells leading to delayed cyclin A degradation [28].
Most often, G1-phase contributes significantly to the
cell cycle duration; thus, we sought to determine the effect
of HSET OE and KD on G1-phase kinetics. Upon gradual
decrease of serum concentration from 10% to 0% over
24h and an additional 12hr serum starvation, transiently
transfected HeLa control vector (CV), HeLa HSET OE
and HeLa HSET KD cells were replenished with serumcontaining medium and stained with “Cell-Clock” dye
(Biocolor; a redox dye that changes color corresponding
to distinct phases in cell cycle). Yellow cells in the culture
represent G1 and their color changes to light green in
S-phase. We followed the proportion of G1 (yellowcolored) cells from 0h (50-70% G1 enrichment) to 9h after
serum replenishment in all the three cases (CV, OE and
KD). We observed negligible differences in the proportion
6082
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of G1 cells in all three conditions (Suppl. Fig. 4Bi, Bii).
This suggests that unlike G2-and M-phase kinetics, HSET
OE does not significantly affect the duration of G1-phase.
Faster kinetic progression of HeLa-HSET-GFP cells
(through G2- and M) compared to HeLa cells raised the
possibility that G2/M or spindle assembly checkpoint
(SAC) functions may be compromised in HeLa-HSETGFP cells. Mad1 is a critical component of the SAC
along with Mad2, and an imbalance in the Mad1-Mad2

protein ratio results in a damaged SAC causing premature
anaphase entry and chromosome instability [29, 30].
Interestingly, we found that HeLa-HSET-GFP cells
express markedly higher levels of Mad1 with a distinct
nuclear envelope localization compared with parental
HeLa cells (Fig. 6A, B). This observation along with
the known association of HSET with importins, indicate
that HSET might be involved in regulating mitotic entry/
exit and nuclear export [31]. By contrast, there was no

Figure 5: HSET overexpression accelerates cell cycle kinetics. (A) Schematic depicting duration of each cell cycle phas in

HeLa and HeLa-HSET-GFP cells assessed by flow cytometry following synchronization at G1/S border by single thymidine block.. (B)
Cell cycle histograms representing cell cycle profiles of synchronized (i) HeLa and (ii) HeLa-HSET-GFP cells from the point of thymidine
block release (0h) to the point after mitotic exit (14h and 11h, respectively). (C) Dot plots of PI (DNA) vs FITC (MPM-2) showing cells in
G2- (lower box) and M-phase (upper box) specifically during the time of mitotic exit in (i) HeLa and (ii) HeLa-HSET-GFP cells. Two-color
scatter plot (PI vs. GFP) shows two box gates, where the lower box represents G2 population (PI-4N and FITC negative) and upper box
represents M population (PI-4N and FITC positive). G2/M population was represented by double the intensity of PI (4N) as compared with
G1 population (2N). Mouse anti-MPM-2 antibody tagged with anti-mouse Alexa-488 secondary antibody was used as a mitosis-specific
marker, to distinguish G2 and M populations. The time for mitotic exit was determined by assessing the population in the upper gate of
the 2-color scatter plot. A sudden surge in the proportion of mitotic population followed by a rapid fall indicated the time of mitotic exit.
13h was observed as the time of mitotic exit for HeLa cells whereas, 10.5h was the time of mitotic exit for HeLa-HSET-GFP cells. (D)
Immunoblots showing cyclin B1 protein levels in synchronized HeLa and HeLa-HSET-GFP cells following release from thymidine block
at G1/S boundary.
www.impactjournals.com/oncotarget
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significant difference in the levels of Mad2 between the
two cell lines (Fig. 6A), showing that the Mad1-Mad2
balance is highly perturbed in the HeLa-HSET-GFP cells.
Thus we envision that excess HSET directly or indirectly
incapacitates the SAC by disrupting the Mad1/Mad2
balance. The HeLa-HSET-GFP cells thus progress through
the cell cycle rapidly in the presence of compromised
checkpoints, which precipitates a greater likelihood of
generating aneuploidy and, thus, may accelerate the
process of tumor evolution.
Our data from the HeLa-HSET-GFP cells
demonstrate that HSET OE can markedly accelerate the
kinetics of G2 and M (Fig. 5A, B, C). Intriguingly, our
immunohistochemical data from clinical tumor samples
(Fig. 3A) showed strong nuclear localization of HSET. In
order to obtain a deeper understanding of how elevated
HSET levels may hasten progression through G2-and
M-phases of the cell cycle and to exclude the possibility
that faster kinetic progression through the cell cycle
may result from artifactual mislocalization of HSET, we
decided to examine in detail the sub-cellular localization
of this intriguing protein in HeLa cells at various cell cycle
stages. We found that HSET is conspicuously confined
to the nucleus throughout interphase (Suppl. Fig. 5).
Our observations are consistent with the finding that the
Xenopus homolog of HSET, XCTK2, is sequestered in
the nucleus in interphase in a Ran-dependent manner via
the association of the NLS of XCTK2 with importin α/β
[32]. In summary, the nuclear localization of the human
HSET protein in interphase strongly suggests that the
acceleration of the kinetics of G2 may be ascribed to a
hitherto unknown activity of HSET within the nucleus.

HSET overexpression
signaling in cancer cells

upregulates

MB-231-HSET overexpressing cells (Fig. 6D). However,
upon HSET knockdown, marginal or no reduction was
observed in the expression levels of these proteins as
compared with their respective levels in control cells (Fig.
6D). We also observed enhanced Aurora-B kinase activity
as well as elevated expression of cyclin B1, D and A upon
HSET overexpression in MDA-MB-231 cells (Suppl. Fig.
6A). The differential effects observed upon HSET OE
and KD indicated that HSET may not normally be a key
regulator of proliferation and survival pathways. Several
studies [33] have in fact shown that HSET function
is dispensable for the viability of most non-cancerous
cells. However, our OE data strongly suggest that an
elevated level of HSET expression thrusts proliferation
and survival signaling in cancer cells into an “overdrive”
mode. Using immunohistochemical analysis, we also
confirmed that HSET nuclear WI correlated strongly
with survivin WI (r=0.68, p=0.05) and Ki67 WI (r=0.32,
p<0.001) in clinical samples (n=163). In summary, while
HSET plays a non-essential role in regulating survival
signaling in cancer cells, HSET overexpression enhances
both proliferation as well as survival of cancer cells and
perhaps fuels tumor progression by providing cancer cells
with a proliferation and survival advantage. Our data thus
provide evidence that cancer cells may employ auxiliary
pathways/mechanisms, such as those involving the kinesin
motor HSET, to their advantage.
To further explore the physiological role of HSET in
cell survival signaling, we assessed the ability of MDAMB-231 cells with HSET OE or KD to resist UV-induced
apoptosis. To this end, we transiently transfected MDAMB-231 cells with control vector, HSET OE construct
or HSET siRNA (~70% transfection efficiency) 24h
prior to UV irradiation. Following 10 min exposure to
UV-C at 25 J/m2, cells were placed in the incubator for
apoptosis induction for 5h. Lysates were then collected for
determining HSET and cleaved caspase-3 protein levels
(an early marker for apoptosis induction) and cell viability
was determined using trypan blue assay. Western blot
analysis revealed significantly higher cleaved caspase-3
induction in cells with HSET knock-down, whereas cells
with HSET OE showed slightly lower cleaved caspase-3
levels as compared to cells transfected with control
vector (Fig. 6E). These data indicate the ability of HSET
overexpression to promote cell survival in cancer cells.

survival

Tumor cell numbers and tumor growth are not only
a function of rate of cell proliferation but are also crucially
influenced by cell survival and/or apoptosis. Having
ascertained that HSET OE can enhance the kinetics of cell
proliferation in tumors, we wanted to investigate whether
elevated levels of HSET have any impact on the status of
pro-survival signaling in HeLa cells. Immunoblots showed
enhanced survival signaling as evidenced by notably high
survivin and p-Bcl2 levels in HeLa-HSET-GFP cells (Fig.
6C) compared with levels seen in parental HeLa cells. To
investigate if HSET OE affects signaling pathways that
impinge on cell proliferation, or cell survival in breast
cancer cells, we compared levels of some key proliferation,
hypoxia and cell survival markers in parental MDAMB-231 cells with MDA-MB-231-HSET overexpressing
cells and MDA-MB-231-HSET knockdown cells. We
observed enhanced levels of survivin and phosphosurvivin, the hypoxia-induced factor HIF1α, the SAC
protein Mad1 and the mitotic kinase Aurora-B in MDAwww.impactjournals.com/oncotarget

HSET
overexpression
increases
steadystate survivin levels by decreasing its polyubiquitination
Since we observed extensive upregulation of
survivin protein expression as a result of HSET OE and
significant reduction upon HSET KD, we wanted to
determine if HSET occurs in the same protein complex
as survivin and whether HSET OE has any effect on the
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APC/C-dependent proteolysis of survivin.
First, we tested if HSET and survivin
co-immunoprecipitate
with
each
other.
We
immunoprecipitated HSET from whole cell lysates of
MDA-MB-231 cells that carried (i) a control vector,
(ii) an HSET OE plasmid, and (iii) an HSET siRNAbearing construct. Upon probing the immunoprecipitates
for survivin, we confirmed that the anti-HSET antibody

was able to pull down survivin in all the three cases,
with an increased survivin pull down in the cell lysates
overexpressing HSET (Fig. 6Fi). We also confirmed this
association by immunoprecipitating survivin and in turn
probing with HSET antibody (Suppl. Fig. 6B). These data
indicate that HEST binds to survivin either directly or
indirectly.
Since survivin’s role in prosurvival signaling is

Figure 6: HSET overexpression upregulates survival proteins and disrupts balance of checkpoint proteins. (A)

Immunoblots showing HSET, Mad1 and Mad2 protein levels in HeLa and HeLa-HSET-GFP cells. β-actin is used as a loading control for all
western blots. (B) Immunofluorescence micrographs showing Mad1 (green) levels and localization in HeLa and HeLa-HSET-GFP cells. (C)
Immunoblots showing the expression levels of survival proteins (survivn, p-Bcl2) in HeLa and HeLa-HSET-GFP cells. (D) Immunoblots
showing the expression of proteins associated with cell survival, cell cycle regulation, spindle assembly checkpoint and adaptation to
hypoxia in MDA-MB-231 cells (C) compared to MDA-MB-231 cells transiently transfected with HSET-pEGFP plasmid (OE) or HSET
siRNA (KD). (E) Immunoblots showing HSET and cleaved caspase-3 protein expression in MDA-MB-231 cells transiently transfected
with vehicle control, HSET pEGFP plasmid or HSET siRNA, followed by UV-C exposure at 25 J/m2 for 10 min. (Fi) Immunoblots showing
HSET and survivin protein levels in MDA-MB-231 with control vector (CV), with HSET overexpression and with HSET knockdown
when HSET was immunoprecipitated (HSET IP) or not immunoprecipitated (beads only) followed by immunoblotting against survivin.
(Fii) Immunoblots showing survivin immunoprecipitated from MDA-MB-231 cells (CV, OE and KD) and imuunoblotted agaist surviving
and ubiquitin. (G) Schematic model depicting the involvement of HSET in tumor progression and metastasis via a) previously established
mitotic pathways (Green boxes) and interphase-specific pathways suggested by our data (blue boxes). Dotted arrow indicates an unknown
and indirect modulation of various downstream pathways by overexpressed nuclear HSET. C= control GFP vector.
www.impactjournals.com/oncotarget
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strongly regulated by its degradation via ubiquitination
[34], we further set out to test the possibility that
increased HSET binding to survivin protects survivin
from ubiquitination and APC/C-dependent degradation.
In MDA-MB-231 cells transiently transfected with
control vector, HSET-GFP plasmid and HSET siRNA,
we immunoprecipitated survivin and immunoblotted
against survivin and ubiquitin. Intriguingly, we observed
reduced polyubiquitin signals in HSET overexpressing
cells, even though survivin protein levels were extensively
overexpressed in HSET overexpressing cells (Fig. 6Fii) as
observed earlier (Fig. 6D). We also observed marginally
higher ubiquitin levels in HSET KD cells as compared
to control, even though the survivin protein levels
were comparable in both the cases (Fig. 6Fii). These
observations, in sum, uncover a previously unrecognized
role of HSET overexpression in tumor progression via
supplementing prosurvival pathways (Fig. 6G).

‘nuclear’ expression of HSET predominantly in the
interphase cells within high grade tumors as revealed
by immunohistochemical staining suggests that HSET
may perform critical mitosis-independent functions in
aggressive tumors or plausibly lead to more aggressive
phenotypes within tumors; (ii) overexpression of HSET
results in accelerated G2- and M-phases. Faster mitoses
can conceivably arise from severely compromised SAC
function that presumably allows HSET-overexpressing
cells to rapidly traverse mitosis in the presence of
aberrations including chromosome attachment errors.
However, we are aware of the caveat that this mitotic
role of HSET does not provide an alibi for the observed
faster progression through the G2-phase upon HSET
overexpression; (iii) HSET OE in HeLa cells leads
to faster cell-cycle kinetics and enhanced overall
proliferation (Fig. 5A, B, C), and (iv) HSET OE leads to
the upregulation of the expression of phospho-survivin,
Bcl-2, HIF1α, Aurora-B and Mad1, and presumably
upregulates the signaling pathways that lie downstream
of these key regulatory factors. Furthermore, since fewer
than 3% of HeLa cells possess amplified centrosomes
(our unpublished observations), we believe that the proproliferative role of HSET that we have demonstrated in
our study in HeLa cells provides strong evidence for a
centrosome clustering-independent activity of HSET.
To further support the centrosome clusteringindependent aspect of HSET’s role in driving tumor
survival and proliferation, we assessed the effects
of HSET OE and KD in HeLa cells with or without
centrosome amplification. We induced extra centrosomes
in HeLa cells by aphidicolin treatment (20 µM for 48h)
and then compared the effect of HSET OE on expression
of proliferation/survival markers in the HeLa cell lines
bearing normonumerary and supernumerary centrosomes.
The fact that we were able to show higher expression of
proliferation and survival proteins upon HSET OE in the
same cell line regardless of its centrosome status (Suppl.
Fig. 7), asserts the centrosome clustering-independent
role of HSET in driving cell proliferation and survival.
Our data showed that HSET OE leads to an increase in
Mad1 levels without any significant change in the levels
of its partner protein, Mad2. Mad1 overexpression in
HeLa cells has been shown to disrupt the stoichiometric
balance between Mad1 and Mad2 to severely cripple
SAC function leading to aneuploidy and chromosomal
instability [29, 30]. We postulate that this surge in
Mad1 protein levels (Fig. 6A, B) facilitates premature
anaphase entry by titrating the soluble pool of Mad2
and thereby damaging SAC function, and provides a
possible explanation for the speedier execution of mitosis
in HeLa-HSET-GFP cells. In addition, our study has
yielded several novel mechanistic insights regarding the
signaling pathways governed by HSET. Our data indicate
that HSET is actually a key member of an oncoprotein
axis that includes HIF1α and Aurora-B, and controls

DISCUSSION
In recent years, the key role played by the
kinesin-14 protein HSET/KifC1 in centrosome clustering
in cancer cells with supernumerary centrosomes, has
been well established. In addition to its mitotic spindlespecific roles, several other roles of HSET requiring or
independent of its motor activity have been suggested such
as a role in processing early endocytic vesicles [35], rat
spermatogenesis [36] and active transport of bare doublestranded DNA [37]. Although it is presently unclear
whether HSET performs all these functions in cancer cells,
these studies bring to light the possibility that HSET’s
involvement in tumor biology could be multifaceted.
We (Fig. 1A,B) and others [9] have found that a
variety of primary tumors overexpress HSET as compared
to their normal adjacent tissues. Several other threads
of largely correlative and circumstantial evidence have
suggested an involvement of HSET in driving tumor
progression and metastases [9, 11]. However, our study
is the first to explore and obtain several new mechanistic
insights into the pathology of excess HSET in breast
cancer cells. We have firmly cemented the hitherto
anecdotal evidence with experimental data to show
that HSET OE in breast cancer (i) correlates strongly
with aggressiveness of the disease, (ii) is attributable,
at least in part, to amplification of the genomic locus
for this gene, and (iii) promotes tumor cell proliferation
by accelerating cell cycle kinetics. Given the myriad of
clinical implications of these important findings, our study
spotlights the tremendous potential that HSET presents
both as a biomarker of tumor progression and as an
invaluable cancer cell-specific therapeutic target.
Four critical observations lead us to believe that
HSET might have additional roles in driving tumor
progression, independent of its centrosome clustering/
spindle pole focusing role in mitosis, viz., (i) elevated
www.impactjournals.com/oncotarget
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survival signaling through phospho-survivin and Bcl-2
(Fig. 6A, C, D). The dysregulation of HIF1α and Aurora-B
are implicated in many aspects of cancer development
and advancement [38, 39]. Notably, HIF1α drives the
expression of survivin, which performs a dual function:
it is an anti-apoptotic protein that additionally promotes
cell proliferation [40-42]. Aurora-B is a chromosomal
passenger protein involved in chromosome segregation,
the spindle checkpoint and cytokinesis [43]. Aurora-B
overexpression, observed in several tumor types [44], has
been linked with aggressive metastasis and poor prognosis
of cancer patients [45, 46]. Our data thus suggest that
HSET OE-driven elevation in HIF1α and Aurora-B
kinase levels incites upregulation of the pro-proliferative
and pro-survival signaling networks and together with the
increased aneuploidy triggered by impaired SAC function,
facilitates tumor evolution into more malignant forms.
Importantly, our immunoprecipitation experiments
demonstrate that both HSET and survivin exist within
the same complex in MDA-MB-231 cells. We further
investigated the molecular and functional significance
of HSET’s association with survivin and uncovered
that HSET binding to survivin protects survivin from
degradation by interfering with the latter’s ubiquitination.
It has been shown that survivin ubiquitination and
degradation occurs in the nucleus. We propose that
high levels of nuclear HSET inhibit the ubiquitinationdependent proteolysis of survivin in the interphase
nucleus of cancer cells. Survivin accumulation is known to
increases Aurora-B kinase activity, which in turn,vincrease
the endogenous levels of phosphorylated histone H3;
clearly, we observe all these effects following HSET OE
(Fig. 6). Thus, we have provided mechanistic evidence
that HSET OE, by stabilizing survivin, leads concurrently
to both increased cell proliferation and survival signaling.
A recent study revealed HSET (along with other
cell cycle regulated genes) as a transcriptional target of
p110CUX1 [47]. Constitutive activation of p110CUX1
is known to drive cell proliferation by expediting entry
into S-phase [48]. Interestingly, Mad1 is also shown to be
transcriptionally regulated by p110CUX1 [49]. In light of
these insights, we are unable to rule out the possibility that
HSET nuclear overexpression and upregulation of Mad1
levels are a mere consequence of an upstream regulation
by classical tumor promoting genes. The Cux1-E2F-HSET
cell proliferation axis thus demands further exploration in
order to substantiate the validity of this prospect. Besides,
we cannot discount the significance of substantial cell
cycle effects observed upon HSET overexpression and the
unyielding relationship between HSET nuclear expression
and patient survival.
Taken together, our results provide compelling
evidence that HSET OE drives tumor progression through
multiple mechanisms that include (i) enhancement of
tumor cell proliferation rates, (ii) increasing aneuploidy
through centrosome clustering, upregulation of Aurora-B
www.impactjournals.com/oncotarget

and compromised SAC function and (iii) promoting
pro-survival signaling. Clearly, these findings that argue
for the existence of a causative link between nuclear
HSET accruement and tumor aggressiveness, have farreaching clinical implications, including unlocking
the potential of HSET nuclear expression serving as a
prognostic biomarker, and HSET taking shape as a cancerselective therapeutic target for the design and preclinical
development of small-molecule HSET inhibitors for nontoxic breast cancer therapy.

MATERIALS AND METHODS
In silico analysis of HSET gene expression
One channel micro array data were collected from
the Gene Expression Omnibus (GEO) database and
processed using Robust Multiarray (RMA) normalization
and were further used for gene expression analysis. The
list of the GSE ID’s are given in Supp. Table 1. Log2transformed HSET expression levels are plotted in Fig. 1
for each of the glioblastoma, lung, breast, colon cervical
cancer and leukemia patients compared with their normal
pairs. Statistical analysis was performed using Student’s
t-test. The criterion for statistical significance was p< 0.05.

Clinical tissue samples
All paraffin-embedded tissue slides were
commercially obtained (from Accumax and US Biomax).
A subset of well-annotated tissue microarrays (339
biospecimens) with information on clinical outcomes
(n=163) were obtained from Emory University Hospital.
The Emory Institutional Review Board approval was
obtained for all aspects of the study.

Immunohistochemistry, scoring and statistics
For immunohistochemical staining, the TMAs
were first deparaffinized and then rehydrated in a series
of ethanol baths (100%, 90%, 75% and 50%). Antigen
retrieval was achieved by citrate buffer (pH 6.0) in a
pressure-cooker (15 psi) for 30 min. Immunostaining for
HSET (1:1000 dilution) was performed using a rabbit
polyclonal antibody which was a generous gift from
Claire Walczak (Indiana University). Enzymatic antibody
detection was performed using Universal LSAB + kit/HRP
(DAKO, CA, USA). HSET staining was scored for both
the nuclear and cytoplasmic localization as an intensity
and frequency score by an experienced pathologist. A
relative intensity score was represented as 0 = none, 1 =
low, 2 = moderate, or 3 = high and frequency score was
represented as the percentage of cell nuclei or cytoplasms
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demonstrating HSET positivity.

Statistical analyses were performed using SAS
Version 9.3 with HSET WI considered as a continuous
variable in all the required analysis tests. Kaplan-Meier
survival curves were generated for patient outcomes (OS
and PFS) stratified by negative and positive HSET WI
groups. Survival differences between the groups were
assessed using the log-rank test.

MO, USA). Antibodies against γ-tubulin, α-tubulin and
β-actin were from Sigma (St. Louis, MO, USA). AntiMad2 antibody was from BD Biosciences (Pharmingen,
San Jose, CA, USA). Antibodies against p-Bcl2 and
cleaved caspase-3 were from Cell Signaling (Danvers,
MA, USA). Alexa 488- or 555- conjugated secondary
antibodies were from Invitrogen (Carlsbad, CA, USA).
Anti-Mad1 antibody was a generous gift from Andrea
Musacchio affiliation. Anti-Ki67 antibody was from
Abcam (Cambridge, MA, USA). Horseradish peroxidaseconjugated secondary antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).

Cell culture and transfection

Kinase activity assay

HeLa-HSET-GFP cells were generously provided
by Claire Walczak (Indiana University). HeLa, HeLaHSET-GFP and MDA-MB-231 cells were grown in
DMEM supplemented with 10% FBS and 1% penicillin/
streptomycin. Briefly, cells were seeded onto 100-mm
plates 1 day prior to transfection. Plasmid DNA (5 μg)
and 15 μl of DharmaFECT 4 transfection reagent (Thermo
Scientific, PA, USA) were used for each transfection.
HSET-pEGFP plasmid was generously provided by Dr.
Walczak. Cells overexpressing HSET were selected in
the medium containing G418 (400 μg/ml). The G418resistant colonies were collected and examined for HSET
expression. SMARTpool: ON-TARGETplus KIFC1
siRNA (Dharmacon, PA, USA) was used to knockdown
HSET in MDA-MB-231 cells.

To examine cdk1 and Aurora-B kinase activity,
respective primary antibodies were used to selectively
immunoprecipitate protein-containing complexes from
cell lysates. The resulting immunoprecipitate was
incubated with pure histone-H3 protein in the presence
of 32P-labelled ATP and kinase buffer. The kinase
assay reaction allowed immunoprecipitated cdk1 to
phosphorylate histone-H3 in vitro, the extent of which was
measured by immunoblotting using phosphohistone-H3
antibody from Cell Signaling (MA, USA). Histone-H3
protein was from Millipore (MA, USA) and ATP was from
Cell Signaling.

Cellular protein preparation, western blotting,
immunofluorescence and antibodies

The samples from tumor cell lines or tumor tissue
were hybridized by 2-color FISH with an HSET-specific
BAC probe (RPCI-11 602P21, green) and a chromosome
6 centromere probe (CH514-7B4, red) (BACPAC). The
HSET and centromere 6 probes were labeled with Cy3dUTP (red) and FITC-dUTP (green), respectively, and
hybridized with nuclei from cell lines or tumor tissue
samples. Plasmids for production of a particular FISH
probe were combined in equimolar amounts (55–70 pM).
Nick translation was performed on 2 µg of this substrate
by using Nick translation kit (Abbott Molecular, IL,
USA). The translation product was denatured for 3 mins
at 95°C followed by fast cooling on ice and confirmed in
1.5% agarose gel electrophoresis as a smear of fragments
ranging between 100 and 300 bp. A 2 min denaturation
at 76°C was followed by overnight (12–16h) incubation
at 37°C. Hybridization of the FISH probes was carried
out in LSI/WCP hybridization buffer (Abbott Molecular,
IL, USA). The slides were counterstained with DAPI
(Invitrogen, NY, USA) and Zeiss LSM 700 confocal
microscope was used to capture FISH images. Results
were expressed as a ratio of the number of copies of the
HSET gene to the number of chromosome 6–centromeric
markers.

Statistical methods

Fluorescence in situ hybridization

Cells were cultured to ~70% confluence and protein
lysates were collected following transfection or otherwise.
Fresh frozen tissue sections were first sonicated and
lysates were then prepared. The immune-reactive bands
corresponding to the respective primary antibodies
were visualized by the Pierce ECL chemiluminescence
detection kit (Thermo Scientific). β-actin was used
as loading control. For immunofluorescence staining,
cells grown on glass coverslips were fixed with −20 °C
methanol for 10 min and blocked by incubating with 2%
bovine serum albumin/PBS/0.05% Triton X-100 at 37 °C
for 1h. Specific primary antibodies were incubated with
coverslips for 1h at 37 °C at the recommended dilution.
The cells were washed with 2% bovine serum albumin/
PBS for 10 min at room temperature before incubating
with a 1:2000 dilution of Alexa 488- or 555-conjugated
secondary antibodies. Cells were mounted with Prolong
Gold antifade reagent that contains 4′,6-diamidino-2phenylindole (Invitrogen). Polyclonal rabbit anti-HSET
antibody was provided by Dr. Claire Walczak. Antibodies
against α-tubulin and β-actin were from Sigma (St. Louis,
www.impactjournals.com/oncotarget
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Flow cytometry

survivin antibodies. After overnight incubation at 4°C,
protein A-agarose beads were added and left at 4°C
overnight. Immunocomplexes were then subjected to
Western blot analysis as described previously. Western
blot analysis with anti-ubiquitin antibody (Life Sensors,
PA, 1:500) was performed by first incubating the PVDF
membrane with 0.5% glutaraldehyde/PBS pH 7.0 for 20
min and then probing for the antibody.

Trypsinized cells were resuspended in PBS at 106
cells/ml. Cells were then fixed by addition of ice-cold
70% ethanol. Ethanol-fixed cells were kept overnight at
4°C before staining. Cells were pelleted and washed twice
with PBS. Cell pellets were incubated for an hour at room
temperature with mouse anti-MPM-2 antibody (Millipore,
MA, USA), followed by1h incubation with Alexa-488
anti-mouse secondary antibody (Life Technologies,
NY, USA). Finally cells were washed, pelleted and
resuspended in PI containing isotonic buffer (0.1 mg/
ml) and 0.5% Triton X-100. Cell cycle distribution was
determined by flow cytometry using an LSRFortessa Flow
cytometer (BD Biosciences, CA, USA) and analyzed
using Flowjo software (Tree Star, OR, USA).
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Trypan Blue cell exclusion assay
Cells were cultured to ~70% confluence followed
by centrifuging and pellet was resuspended in 1 ml culture
medium. 0.1 mL of 0.4% trypan blue solution was then
added to 1 mL of cell suspension. A hemacytometer
was loaded with 10 µl of the solution and examined
immediately under a microscope. Live (white) and dead
(blue) cells were counted and percent cell viability was
calculated using the following formula: percent viable
cells = [1.00 – (Number of live cells ÷ Number of total
cells)] × 100.
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